In summary, we identified the large-effect CNV segments that explain the variance of response to the treatment with TNF-α blockers in the Korean patients with RA based on common disease activity indexes—ΔDAS28 and ΔCDAI, suggesting as a potential biomarker to predict efficacy prior to the treatment of TNF-α blockers. Here, TNF is linked to rheumatoid arthritis.